Jazz Pharmaceuticals (JAZZ) Q3 2025 earnings summary

Executive summary

• Achieved record quarterly revenue of $1.13 billion in Q3 2025, up 7% year-over-year, driven by strong growth in Xywav, Epidiolex, and the launch of Modeyso.

• Secured FDA approvals for Modeyso (first for recurrent H3 K27M-mutant DMG) and Zepzelca plus Tecentriq/atezolizumab for first-line maintenance in small cell lung cancer.

• Completed acquisition of Chimerix, adding Modeyso to the oncology portfolio, and entered a global licensing agreement with Saniona for SAN2355, expanding the epilepsy pipeline.

• Settled major Xyrem antitrust and Avadel litigation, removing key legal uncertainties and incurring significant charges.

• Welcomed Dr. Ted Love to the Board of Directors, enhancing leadership depth.

Financial highlights

• Q3 2025 total revenue reached $1.13 billion, a 7% increase year-over-year, with Xywav net sales up 11% to $431 million and Epidiolex up 20% to $303 million.

• Oncology product revenue increased 1% to $288 million, with Modeyso generating $11 million in its launch quarter.

• GAAP net income for Q3 2025 was $251.4 million ($4.08 per diluted share), up from $215.1 million in Q3 2024; non-GAAP adjusted net income was $501 million ($8.13 per share).

• Gross margin for Q3 2025 was 87.9% (GAAP) and 92.2% (non-GAAP); operating expenses increased due to litigation settlements and integration costs.

• Cash and investments at quarter-end totaled $2.0 billion, with $993 million in operating cash flow for the first nine months of 2025.

Outlook and guidance

• 2025 revenue guidance narrowed to $4.175–$4.275 billion, with non-GAAP adjusted net income projected at $475–$525 million and EPS guidance raised to $7.65–$8.45.

• Guidance reflects litigation settlements, Chimerix acquisition, and Saniona licensing agreement.

• Anticipates generic entry for Xyrem in 2026, with potential payer actions impacting Xywav revenue.

• Expects Epidiolex to achieve blockbuster status in 2025.

• Top-line results from the phase III Zanidatamab HERIZON-GEA trial expected later this quarter.